[
  {
    "ts": "2025-11-19T04:29:41+00:00",
    "headline": "Is Moderna (MRNA) Undervalued? Examining the Latest Valuation Narrative and Investor Sentiment",
    "summary": "Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up the company's revenue growth alongside its ongoing net losses, especially as the biotech sector faces headwinds. See our latest analysis for Moderna. After a tough year, Moderna’s share price sits at $24.92, down more than 40% year-to-date, while its total shareholder return over the past 12 months is also in firmly negative territory. Momentum has faded as investors...",
    "url": "https://finance.yahoo.com/news/moderna-mrna-undervalued-examining-latest-042941387.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b47c9b2a-09a0-3a91-8250-fb4c0cc11c75",
      "content": {
        "id": "b47c9b2a-09a0-3a91-8250-fb4c0cc11c75",
        "contentType": "STORY",
        "title": "Is Moderna (MRNA) Undervalued? Examining the Latest Valuation Narrative and Investor Sentiment",
        "description": "",
        "summary": "Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up the company's revenue growth alongside its ongoing net losses, especially as the biotech sector faces headwinds. See our latest analysis for Moderna. After a tough year, Moderna’s share price sits at $24.92, down more than 40% year-to-date, while its total shareholder return over the past 12 months is also in firmly negative territory. Momentum has faded as investors...",
        "pubDate": "2025-11-19T04:29:41Z",
        "displayTime": "2025-11-19T04:29:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lV6Oo0M_C3X63uXoBkpnwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KdbFtaQiMRVA6Enl712wNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-undervalued-examining-latest-042941387.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-undervalued-examining-latest-042941387.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]